Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Viracta Therapeutics Inc (VIRX)

Viracta Therapeutics Inc (VIRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,620
  • Shares Outstanding, K 39,272
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,060 K
  • 60-Month Beta 0.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade VIRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.16
  • Most Recent Earnings $-0.25 on 08/14/24
  • Next Earnings Date 08/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 625.92% ( +359.25%)
  • Historical Volatility 106.21%
  • IV Percentile 86%
  • IV Rank 46.80%
  • IV High 1,281.03% on 03/08/24
  • IV Low 49.68% on 01/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 405
  • Open Int (30-Day) 399

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.21
  • Number of Estimates 1
  • High Estimate -0.21
  • Low Estimate -0.21
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +36.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2020 +9.85%
on 08/27/24
0.3181 -30.24%
on 08/20/24
-0.0710 (-24.24%)
since 08/19/24
3-Month
0.2020 +9.85%
on 08/27/24
0.6490 -65.81%
on 06/21/24
-0.3891 (-63.68%)
since 06/18/24
52-Week
0.2020 +9.85%
on 08/27/24
1.3100 -83.06%
on 04/12/24
-0.8981 (-80.19%)
since 09/19/23

Most Recent Stories

More News
Sunesis: Q2 Earnings Snapshot

Sunesis: Q2 Earnings Snapshot

VIRX : 0.2200 (+0.23%)
Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth

/PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the succession...

VIRX : 0.2200 (+0.23%)
Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases

/PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the...

VIRX : 0.2200 (+0.23%)
Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

Continued progress of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s)...

VIRX : 0.2200 (+0.23%)
Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award

/PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that its...

VIRX : 0.2200 (+0.23%)
Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

/PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiation...

VIRX : 0.2200 (+0.23%)

Business Summary

Viracta Therapeutics Inc. is a precision oncology company targeting virus-associated malignancies. The company is pursuing application of inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma and other virus-related cancers. Viracta...

See More

Key Turning Points

3rd Resistance Point 0.2329
2nd Resistance Point 0.2264
1st Resistance Point 0.2230
Last Price 0.2200
1st Support Level 0.2131
2nd Support Level 0.2066
3rd Support Level 0.2032

See More

52-Week High 1.3100
Fibonacci 61.8% 0.8867
Fibonacci 50% 0.7560
Fibonacci 38.2% 0.6253
Last Price 0.2200
52-Week Low 0.2020

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar